Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival

Bijay Nair, John D. Shaughnessy, Yiming Zhou, Marie Astrid-Cartron, Pingping Qu, Frits Van Rhee, Elias Anaissie, Yazan Alsayed, Sarah Waheed, Klaus Hollmig, Jackie Szymonifka, Nathan Petty, Antje Hoering, Bart Barlogie

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

We report on prognostic implications for postrelapse survival (PRS) of a gene expression profiling (GEP)-defined risk score at relapse available in 120 myeloma patients previously enrolled in tandem transplantation trial Total Therapy 2. Among the 71 patients with additional GEP baseline information, 3-year PRS was 71% in 40 patients with low risk present both at baseline and relapse contrasting with only 17% in 28 patients with high risk at relapse, 12 of whom with baseline low-risk status fared better than the remainder (P = .08). On multivariate analysis of relapse parameters available in 104 patients, high risk conferred short PRS (hazard ratio = 4.00, P < .001, R2 = 33%), whereas relapse hyperdiploidy predicted long PRS (hazard ratio = 0.37, P = .022, cumulative R2 = 41%). In case the initial partial response lasted less than 2 years, relapse low-risk identi-fied 26 patients with superior 3-year PRS of 61% versus 9% among 32 with relapse high-risk (P < .001). Based on its PRS predictive power, GEP analysis should be an integral part of new agent trials in search of better therapy for high-risk myeloma.

Original languageEnglish (US)
Pages (from-to)3572-3575
Number of pages4
JournalBlood
Volume113
Issue number26
DOIs
StatePublished - 2009

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival'. Together they form a unique fingerprint.

  • Cite this

    Nair, B., Shaughnessy, J. D., Zhou, Y., Astrid-Cartron, M., Qu, P., Van Rhee, F., Anaissie, E., Alsayed, Y., Waheed, S., Hollmig, K., Szymonifka, J., Petty, N., Hoering, A., & Barlogie, B. (2009). Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. Blood, 113(26), 3572-3575. https://doi.org/10.1182/blood-2009-02-207803